Literature DB >> 3349575

Reactivity of isolated porcine coronary resistance arteries to cholinergic and adrenergic drugs and transmural pressure changes.

K Nakayama1, G Osol, W Halpern.   

Abstract

The reactivity of porcine intramyocardial resistance arteries (223 +/- 7 micron i.d., n = 30) was investigated with a pressurized in vitro preparation. Diameter changes in response to acetylcholine and to adrenergic drugs and dynamic changes in transmural pressure changes were investigated. Acetylcholine produced concentration-dependent constrictions, causing maximal reductions of 71 +/- 3% in lumen diameter, with EC50 values averaging 1.9 X 10(-7) M (n = 7). These responses were inhibited by atropine (10(-7) M) and therefore were mediated by muscarinic receptors. In addition, acetylcholine did not elicit relaxation in nine out of 10 vessels precontracted with U46619 (10(-7) M). Norepinephrine and epinephrine never produced constrictions (n = 6) even in the presence of propranolol (10(-6) M). Both norepinephrine and isoproterenol caused dose-dependent relaxations in acetylcholine-precontracted vessels, with IC50 values of 8.2 X 10(-7) M (n = 5) and 6.6 X 10(-8) M (n = 6), respectively. These relaxations were suppressed by propranolol. Between transmural pressures of 10 and 90 mm Hg, there was no intrinsic myogenic tone (n = 7). In addition, the vessels responded only passively to sudden pressure changes of 40 mm Hg. In all vessels, the functional integrity of the endothelium was verified by relaxations to substance P (10(-8) M) and/or bradykinin (10(-8) M).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349575     DOI: 10.1161/01.res.62.4.741

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Muscarinic cholinergic receptors in the human right coronary artery: a receptor binding and autoradiographic study.

Authors:  F Amenta; M De Michele; P Strocchi; F Ferrante; P Gallo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

Review 2.  Coronary microcirculation: autoregulation and metabolic control.

Authors:  D V DeFily; W M Chilian
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

3.  Acetylcholine-induced vasoconstrictor response of coronary vessels in rats: a possible contribution of M2 muscarinic receptor activation.

Authors:  Y Nasa; H Kume; S Takeo
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 4.  alpha-adrenergic responses of isolated canine coronary microvessels.

Authors:  C J Jones; L Kuo; M J Davis; W M Chilian
Journal:  Basic Res Cardiol       Date:  1995 Jan-Feb       Impact factor: 17.165

5.  Strong Relationship Between Vascular Function in the Coronary and Brachial Arteries.

Authors:  Ryan M Broxterman; Melissa A Witman; Joel D Trinity; H Jonathan Groot; Matthew J Rossman; Song-Young Park; Simon Malenfant; Jayson R Gifford; Oh Sung Kwon; Soung Hun Park; Catherine L Jarrett; Katherine L Shields; Jay R Hydren; Angela V Bisconti; Theophilus Owan; Anu Abraham; Anwar Tandar; Charles Y Lui; Brigham R Smith; Russell S Richardson
Journal:  Hypertension       Date:  2019-05-06       Impact factor: 10.190

6.  Heterogeneity of muscarinic receptors in lamb isolated coronary resistance arteries.

Authors:  U Simonsen; D Prieto; L Rivera; M Hernández; M J Mulvany; A García-Sacristán
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension.

Authors:  A M Zeiher; H Drexler; B Saurbier; H Just
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Role of Coronary Myogenic Response in Pressure-Flow Autoregulation in Swine: A Meta-Analysis With Coronary Flow Modeling.

Authors:  Gregory M Dick; Ravi Namani; Bhavesh Patel; Ghassan S Kassab
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.